Tackling cardiometabolic risk in the Asia Pacific region.

Autor:	Li JJ; State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China., Yeo KK; National Heart Centre Singapore and Duke-NUS Medical School, Singapore., Tan K; Department of Medicine, University of Hong Kong; Kitasato University, Sagamihara, Japan., Ako J; Kitasato University, Sagamihara, Japan., Krittayaphong R; Division of Cardiology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand., Tan RS; National Heart Centre Singapore and Duke-NUS Medical School, Singapore., Aylward PE; South Australian Health and Medical Research Institute and Flinders University, Adelaide, Australia., Lam CP; National Heart Centre Singapore and Duke-NUS Medical School, Singapore., Baek SH; Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Dalal J; Kokilaben Hospital, Mumbai, India., Fong A; Department of Cardiology, Sarawak Heart Centre; and Clinical Research Centre, Sarawak General Hospital, Kuching, Malaysia., Li YH; National Cheng Kung University Hospital, Tainan, Taiwan., O'Brien RC; University of Melbourne and Austin Health, Melbourne, Australia., Koh SYN; National Heart Centre Singapore and Duke-NUS Medical School, Singapore., Scherer DJ; South Australian Health and Medical Research Institute, Australia., Tada H; Kanazawa University Graduate School of Medicine, Kanazawa, Japan., Kang V; Singapore Heart Foundation, Singapore., Butters J; Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Melbourne, Australia., Nicholls SJ; Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Melbourne, Australia.
Jazyk:	angličtina
Zdroj:	American journal of preventive cardiology [Am J Prev Cardiol] 2020 Nov 08; Vol. 4, pp. 100096. Date of Electronic Publication: 2020 Nov 08 (Print Publication: 2020).
DOI:	10.1016/j.ajpc.2020.100096
Abstrakt:	With the global spread of abdominal obesity, cardiovascular disease continues to spread to all countries of the world. Given the large population, the challenges presented by cardiometabolic risk in the Asia Pacific region are considerable. In addition to the clinical consequences of cardiovascular disease, in terms of its morbidity and mortality, the diversity of the Asia Pacific region brings heterogeneity in approaches to prevention, diagnosis and treatment of cardiometabolic risk. In this manuscript, we will review the current state of knowledge of cardiometabolic risk in Asia Pacific and highlight the needs moving forward to tackle this public health challenge. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. KKY has received research grants from Amgen, Astra Zeneca, Bayer, Boston Scientific, Biofourmis, Holmusk, is a consultant for Abbott Vascular, Boston Scientific, Medtronic, Medopad, Bayer and speaker for Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Philips, Alvimedica, Bayer, Biotronik, Orbus Neich; JA has received honoraria from Sanofi and Astellas-Amgen; CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cytokinetics, Darma Inc., Eko.ai Pte Ltd, JanaCare, Janssen Research & Development LLC, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk, Radcliffe Group Ltd., Roche Diagnostics, Stealth BioTherapeutics, The Corpus, Vifor Pharma and WebMD Global LLC.; and serves as co-founder & non-executive director of EKo.ai Pte Ltd; AF is a speaker and consultant for AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Pfizer, Novartis, Roche Diagnostics, Siemens, Medtronic, Boston Scientific, and OrbusNeich Medical and received research grants from Boehringer Ingelheim, and Medtronic; RCO is a consultant or speaker for MSD, Mylan, Amgen and Sanofi; SJN has received research support from AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and is a consultant for AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. All other authors have no relationships to disclose. (© 2020 Published by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu